Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-authorization safety study of HX575 epoetin alfa i.v. in CKD patients
2007-005728-34Phase 4Completed
- Sponsor
- Hexal AG
- Start
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoetin alfa in anaemia and anemia of renal disease, sponsored by Hexal AG. Primary endpoints: Incidence of relevant drug-related adverse events and Incidence of EPO-related lack of efficacy. Started Feb 2008; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anaemiaanemia of renal disease
Beyond the preview
Go deeper on 2007-005728-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005728-34.